Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Safonov · SciRah

Researcher profile · Semantic Scholar

A. Safonov

Share profile

A. Safonov — researcher profile on SciRah

h-index: 12
Works: 66
Citations: 682

Most-cited papers

Automated real-world data integration improves cancer outcome prediction
J. Jee, Christopher J. Fong, K. Pichotta, T. Tran +64 more
2024Nature174 citations Open access
Semantic Scholar
Clonal hematopoiesis is associated with risk of severe Covid-19
K. Bolton, Y. Koh, M. Foote, Hogune Im +41 more
2020Nature Communications125 citations Open access
Semantic Scholar
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
R. Kudo, A. Safonov, Catherine Jones, E. Moiso +24 more
2023bioRxiv65 citations Open access
Semantic Scholar
Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort
K. Arora, T. Tran, Y. Kemel, Miika Mehine +24 more
2022Cancer Discovery59 citations Open access
Semantic Scholar
Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer
Sungsoo Kim, Jessica Armand, A. Safonov, Mi-Mi Zhang +8 more
2023Cell Reports45 citations Open access
Semantic Scholar
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Avantika Gupta, A. Gazzo, P. Selenica, A. Safonov +24 more
2025Nature Genetics26 citations Open access
Semantic Scholar
Clinical management of TP53 mosaic variants found on germline genetic testing
A. Ward, Dana Farengo-Clark, Danielle B. McKenna, A. Safonov +9 more
2024Cancer Genetics20 citations Open access
Semantic Scholar
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Avantika Gupta, A. Gazzo, P. Selenica, A. Safonov +21 more
2024bioRxiv17 citations Open access
Semantic Scholar
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms
F. Pareja, H. Dopeso, Yi-Kan Wang, A. Gazzo +35 more
2024Cancer Research16 citations Open access
Semantic Scholar
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
A. Safonov, Antonio Marra, C. Bandlamudi, Ben O'Leary +36 more
2024bioRxiv14 citations Open access
Semantic Scholar
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
N. Mai, C. D. dos Anjos, P. Razavi, A. Safonov +11 more
2024npj Breast Cancer13 citations Open access
Semantic Scholar
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
Yi Tai, Angela Chow, Seoyoung Han, C. Coker +15 more
2024EMBO Molecular Medicine12 citations Open access
Semantic Scholar
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
A. Safonov, Min-Na K. Lee, David N. Brown, Luca Boscolo Bielo +53 more
2026Nature11 citations Open access
Semantic Scholar
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Rei Kudo, A. Safonov, Catherine Jones, E. Moiso +23 more
2024Cancer Cell11 citations Open access
Semantic Scholar
Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.
A. Safonov, C. Bandlamudi, P. Selenica, A. Marra +11 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
Abstract HER2-07: HER2-07 Genomic Characterization of Primary and Metastatic HER2-low Breast Cancers
A. Marra, A. Safonov, J. Drago, E. Ferraro +7 more
2023Cancer Research8 citations
Semantic Scholar
Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
Sonya M. Chew, E. Ferraro, A. Safonov, Yuan Chen +4 more
2024European Journal of Cancer7 citations Open access
Semantic Scholar
210P Real-world outcomes in patients (pts) with HR+/HER2– metastatic breast cancer (mBC) and germline/tumour BRCA mutations (g/tBRCA1/2m) receiving 1st-line (1L) CDK4/6i plus endocrine therapy (ET)
A. Safonov, E. Nizialek, I. Gibson, S. Khosla +5 more
2023ESMO Open5 citations Open access
Semantic Scholar
210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
A. Marra, A. Gazzo, A. Gupta, P. Selenica +11 more
2022Annals of Oncology5 citations Open access
Semantic Scholar
Oxygen Transport in Bioreactors for Engineered Vascular Tissues
Jason W. Bjork, A. Safonov, R. Tranquillo
20125 citations
Semantic Scholar
CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer.
Antonio Marra, P. Selenica, Ying-Jie Zhu, A. Safonov +10 more
2024Journal of Clinical Oncology4 citations
Semantic Scholar
Impact of Clonal Hematopoiesis on Solid Tumor Progression Following Radiation Therapy
Jacqueline J. Tao, J. Setton, Pablo Sánchez Vela, A. Safonov +9 more
2025JCO Precision Oncology3 citations
Semantic Scholar
Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
P. Razavi, Mehnaj S. Ahmed, Ashley Roush, Rohan C. Parikh +13 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy
L. Cabel, J. An, H. Kim, Jisun Kim +17 more
2026npj Breast Cancer2 citations Open access
Semantic Scholar
Abstract GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer
E. Moiso, E. Ferraro, L. Cabel, A. Safonov +10 more
2025Clinical Cancer Research2 citations
Semantic Scholar
Integration of Next Generation Sequencing Data to Inform Survival Prediction of Patients with Spine Metastasis
Alexandra M. Giantini-Larsen, Alexander Ramos, Axel Martin, K. Panageas +9 more
2025Cancers2 citations
Semantic Scholar
Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer.
N. Mai, Bo Liu, A. Safonov, Sherry Shen +8 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach.
E. Moiso, E. Ferraro, L. Cabel, A. Safonov +8 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
S. Wander, C. Weipert, Jie-Min Liao, A. Safonov +3 more
2023Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Abstract 1787: Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer
Bo Liu, J. Drago, Yi Rao, P. Pereira +9 more
2022Cancer Research2 citations
Semantic Scholar
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.
C. Bandlamudi, D. Muldoon, I. de Bruijn, Mingxuan Zhang +85 more
2026Cancer Cell1 citations Open access
Semantic Scholar
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer
Sherry Shen, J. Teysir, A. Safonov, Maria Bromberg +4 more
2026Breast Cancer Research1 citations Open access
Semantic Scholar
Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer.
S. Wander, C. Weipert, L. Cabel, J. Liao +4 more
2026npj Breast Cancer1 citations Open access
Semantic Scholar
Genomic predictors of brain metastases in breast cancer.
A. Safonov, D. Smith, Subhiksha Nandakumar, E. Ferraro +12 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.
E. Ferraro, E. Moiso, A. Safonov, L. Cabel +8 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.
S. Shen, A. Safonov, Maria Bromberg, Yuan Chen +3 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract PS12-03: p53 loss enables HR+ breast cancer escape from CDK4/6 inhibitor-induced quiescence via CDK2
Rei Kudo, A. Safonov, E. D. da Silva, Qing Li +10 more
2024Cancer Research1 citations
Semantic Scholar
Abstract P4-02-01: Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer
E. Ferraro, A. Safonov, Yuan Chen, Charlie White +11 more
2023Cancer Research1 citations
Semantic Scholar
Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival
J. Jee, Christopher Fong, K. Pichotta, T. Tran +21 more
2023Cancer Research1 citations
Semantic Scholar
Abstract P4-08-12: Clinical and Genomic Landscape of Breast Cancers Carrying CCNE1 Amplification
A. Marra, P. Selenica, Ying-Jie Zhu, P. Razavi +4 more
2023Cancer Research1 citations
Semantic Scholar
Oral estrogen receptor (ER) degraders compared to standard endocrine therapy (ET) in ER-positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC): A systematic review and meta-analysis.
Hadar Goldvaser, S. Khutsurauli, Michèle Buchinger, A. Safonov +1 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract PS2-08-05: Multimodal integration of real world genomic and clinical data for the prediction of brain metastasis development in breast cancer
A. Safonov, D. Smith, S. Nandakumar, L. Boe +13 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Clinical impact and temporal evolution of mutational signatures in metastatic lobular breast cancer.
Sherry Shen, F. Pareja, L. Djerroudi, Xin Pei +7 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer.
N. Mai, Sharanya Nag, Bo Liu, Wan-Yi Chen +12 more
2026Clinical Cancer Research0 citations
Semantic Scholar
An actionable machine learning–driven clinicogenomic model as a predictor of brain metastasis risk in breast cancer.
L. Pike, A. Safonov, Subhiksha Nandakumar, D. Smith +15 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Oral Estrogen Receptor Degraders Compared to Standard Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Hadar Goldvaser, S. Khutsurauli, Michèle Buchinger, A. Safonov +1 more
2026Cancers0 citations Open access
Semantic Scholar
CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer
Luca Boscolo Bielo, F. Sánchez-Vega, Subhiksha Nandakumar, Antonio Marra +32 more
2026Research Square0 citations Open access
Semantic Scholar
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer
Avantika Gupta, A. Gazzo, P. Selenica, A. Safonov +24 more
2025Nature Genetics0 citations Open access
Semantic Scholar
Abstract P3-09-26: Efficacy of trastuzumab deruxtecan (T-DXd) in patients with metastatic lobular breast cancer with or without HER2 mutations: the MSKCC experience
Sherry Shen, A. Safonov, J. Teysir, Mithat Gonen +3 more
2025Clinical Cancer Research0 citations
Semantic Scholar
Abstract P1-11-07: Associations between Breast Cancer Index Classifications and MSK-IMPACT Genomic Profiles in HR+/HER2- Breast Cancer
Hong Zhang, Li Ma, A. Safonov, N. Siuliukina +15 more
2025Clinical Cancer Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Razavi×38
Invite
P. Razavi — researcher profile on SciRah
S. Chandarlapaty×27
Invite
S. Chandarlapaty — researcher profile on SciRah
Mehnaj S. Ahmed×12
Invite
Mehnaj S. Ahmed — researcher profile on SciRah
M. Robson×10
Invite
M. Robson — researcher profile on SciRah

×10

Invite

E. Moiso — researcher profile on SciRah

J. Reis-Filho×10

Invite

J. Reis-Filho — researcher profile on SciRah

Invite

F. Pareja — researcher profile on SciRah

Invite

E. Ferraro — researcher profile on SciRah

Invite

S. Modi — researcher profile on SciRah

Invite

K. Jhaveri — researcher profile on SciRah

Invite

B. Weigelt — researcher profile on SciRah

Invite

P. Selenica — researcher profile on SciRah